Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

RTTNews | 483 days ago
Stocktwits
Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) and Daiichi Sankyo Europe GmbH or DSE, the European arm of Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (DSKYF.PK), announced Wednesday a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet.

DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

The legal action pending in the United States District Court for the Southern District of New York will be dismissed.

Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

Tags: DSKYF.PK ESPR
Stocktwits
read more
Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
RTTNews | 495 days ago
U.S. GDP Unexpectedly Dips In First Quarter As Imports Soar

U.S. GDP Unexpectedly Dips In First Quarter As Imports Soar

The Commerce Department released a report on Wednesday showing the U.S. economy unexpectedly shrank in the first quarter of 2025. The report said real gross domestic product fell by 0.3 percent in the first quarter after surging by 2.4 percent in the fourth quarter of 2024. Economists had expected GDP to rise by 0.4 percent.
RTTNews | 16 minutes ago
U.S. Private Sector Job Growth Falls Well Short Of Expectations In April

U.S. Private Sector Job Growth Falls Well Short Of Expectations In April

Payroll processor ADP released a report on Wednesday showing private sector employment in the U.S. increased by much less than expected in the month of April. ADP said private sector employment climbed by 62,000 jobs in April after surging by a downwardly revised 147,000 jobs in March.
RTTNews | 41 minutes ago
Eurozone GDP Growth Gains Strength In Q1

Eurozone GDP Growth Gains Strength In Q1

Euro area economic growth accelerated in the first quarter as exports may have benefited from higher demand from the U.S. ahead of the imposition of higher trade tariffs. The quarterly growth in gross domestic product doubled to 0.4 percent from 0.2 percent seen in the fourth quarter of 2024, preliminary flash estimates from Eurostat showed on Wednesday.
RTTNews | 53 minutes ago
Indian Rupee Rises On Trade-deal Hopes

Indian Rupee Rises On Trade-deal Hopes

The Indian rupee strengthened against the U.S. dollar in the European session on Wednesday, as investor mood was bolstered by trade-deal prospects and foreign fund inflows.
RTTNews | 1h 31min ago
Canadian Stocks Likely To Open On Mixed Note; GDP Data, Earnings In Focus

Canadian Stocks Likely To Open On Mixed Note; GDP Data, Earnings In Focus

Canadian shares are likely to open on a mixed note on Wednesday with investors looking ahead to earnings updates from big name U.S. tech companies, including Microsoft and Meta Platforms. Canadian GDP data is also likely to make a significant impact on investor sentiment.
RTTNews | 1h 33min ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Press Release
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.